The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Cytomegalovirus Disease in Immunocompromised Hosts

CMV reactivation and disease in transplant, HIV, and immunosuppressed patients

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Internal Medicine department. Book Appointment →

What is Cytomegalovirus Disease in Immunocompromised Hosts?

Cytomegalovirus (CMV, HHV-5) is a beta-herpesvirus with seroprevalence 50-90% in adults. After primary infection, the virus establishes lifelong latency in monocytes, lymphocytes, and tissues. Reactivation in immunocompromised hosts causes major morbidity and mortality. The most clinically affected populations are allogeneic hematopoietic stem cell transplant (HSCT) recipients, solid organ transplant (SOT) recipients (especially lung, intestinal, kidney-pancreas), HIV-infected patients with low CD4, hematologic malignancies, primary immunodeficiencies, and patients on intensive immunosuppression.

Disease manifestations include CMV syndrome (fever, malaise, leukopenia, thrombocytopenia, transaminitis), pneumonitis (most fatal in HSCT), gastrointestinal disease (esophagitis, gastritis, colitis with hemorrhage and perforation), hepatitis, retinitis (HIV with low CD4, transplant), encephalitis, ventriculoencephalitis, polyradiculopathy, adrenal insufficiency, and indirect effects (graft dysfunction, increased rejection, opportunistic infections, malignancy).

Quantitative whole blood or plasma CMV PCR is the primary diagnostic and monitoring tool. Tissue CMV detection (PCR, immunohistochemistry, viral inclusions) confirms tissue-invasive disease. Modern management includes prophylactic letermovir (high-risk allogeneic HSCT) or valganciclovir, preemptive therapy guided by surveillance PCR, and treatment of established disease with intravenous ganciclovir, valganciclovir, foscarnet (resistance or marrow toxicity), cidofovir, maribavir (ganciclovir/foscarnet-resistant), and CMV-specific T cell therapy. Antiviral resistance (UL97 and UL54 mutations) requires alternative regimens.

Symptoms

CMV syndrome: fever, malaise, leukopenia, thrombocytopenia
Transaminitis (mild)
Pneumonitis (cough, dyspnea, hypoxemia, ground-glass opacities)
ARDS-like presentation
Esophagitis (odynophagia, dysphagia, retrosternal pain)
Gastritis, gastroduodenitis (epigastric pain, bleeding)
Colitis (diarrhea, hemorrhage, perforation)
Hepatitis (elevated transaminases, cholestasis)
Retinitis (HIV with CD4 < 50, transplant): floaters, decreased vision, blind spots, characteristic 'pizza pie' fundus
Encephalitis, ventriculoencephalitis
Polyradiculopathy
Adrenal insufficiency
Graft dysfunction (kidney, liver, lung, heart, intestinal)
Allograft rejection (CMV-associated)
Cytopenia post-engraftment HSCT
Mononucleosis-like syndrome in primary infection
Atypical lymphocytes
Indirect effects: increased opportunistic infections (PCP, fungal, bacterial)
Malignancy associations (post-transplant lymphoproliferative disease)
Failure to thrive (pediatric)

Risk Factors

Allogeneic HSCT (highest risk, especially mismatched, cord blood, T-cell depleted, haploidentical)
Solid organ transplantation (lung, intestinal, kidney-pancreas highest risk)
Donor-positive recipient-negative CMV serostatus (D+/R-) — primary infection from graft
Donor-positive recipient-positive (D+/R+) — reactivation
Acute rejection requiring increased immunosuppression
Anti-thymocyte globulin (ATG)
Alemtuzumab
High-dose corticosteroids
HIV with CD4 < 100 (especially < 50)
Hematologic malignancies
Solid tumor chemotherapy
Anti-CD20 (rituximab) therapy
JAK inhibitor therapy (ruxolitinib)
Belimumab, dupilumab (rare)
Severe combined immunodeficiency
Primary immunodeficiency disorders
Inflammatory bowel disease on biologics
Pregnancy (vertical transmission, primary infection greatest risk)
Older age
Coinfection with other herpesviruses

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Routine post-transplant CMV surveillance
  • Fever, leukopenia, transaminitis in immunocompromised patient
  • Respiratory symptoms in transplant recipient
  • Gastrointestinal symptoms in immunocompromised patient
  • Visual symptoms in HIV with low CD4 or transplant patient
  • Encephalopathy in immunocompromised patient
  • Graft dysfunction in transplant patient
  • Failure or delayed engraftment post-HSCT
  • Pre-transplant CMV serostatus assessment
  • Pregnancy with concerns about CMV
  • Newborn with CMV infection (congenital)
  • HIV with new symptoms and low CD4
  • Post-engraftment cytopenia

Treatment Methods

01
Pre-transplant CMV serology of donor and recipient
02
Pre-transplant HIV CMV serology and CD4 count
03
Routine post-transplant surveillance with weekly to bimonthly quantitative whole blood or plasma CMV PCR for first 100 days post-HSCT, first 3-6 months post-SOT, with extension based on risk
04
Comprehensive evaluation: CBC, comprehensive metabolic panel, hepatic function, urinalysis, blood and urine cultures, chest imaging, ophthalmology
05
Bronchoscopy with bronchoalveolar lavage and biopsy for pulmonary disease
06
Endoscopy with biopsy for gastrointestinal disease
07
Brain MRI and lumbar puncture for encephalitis
08
Ophthalmologic evaluation for retinitis
09
Tissue PCR or immunohistochemistry for tissue-invasive disease
10
CMV-specific T cell quantification (CMV-IGRA, ELISpot) emerging in some centers
11
Prophylactic letermovir (240-480 mg daily for 100-200 days post-allogeneic HSCT) — major advance reducing CMV reactivation
12
Prophylactic valganciclovir (typically 900 mg daily for 100-200 days post-SOT) for D+/R- and high-risk D+/R+
13
Preemptive therapy initiation when CMV PCR exceeds threshold (typically 1000-10,000 copies/mL or rising trend) with valganciclovir 900 mg twice daily or IV ganciclovir 5 mg/kg twice daily
14
Treatment of established disease: IV ganciclovir 5 mg/kg twice daily for 14-21 days minimum
15
Switch to valganciclovir 900 mg twice daily after improvement and ability to tolerate orally
16
Foscarnet 60-90 mg/kg every 8 hours for ganciclovir resistance, marrow suppression, or pregnancy
17
Cidofovir 5 mg/kg weekly with probenecid and IV hydration
18
Maribavir 400 mg twice daily for refractory or resistant CMV (FDA-approved 2021)
19
CMV-specific T cell therapy (banked third-party or autologous) for severe refractory disease
20
Reduction of immunosuppression when possible
21
Resistance testing (UL97, UL54) when treatment failure suspected
22
Hyperimmune globulin (CytoGam) for refractory pneumonitis (limited evidence)
23
Topical or intraocular ganciclovir for retinitis (less common with effective systemic therapy)
24
Long-term suppression in HIV with CD4 < 100 until immune reconstitution
25
Routine ophthalmology screening in HIV with low CD4
26
Treat coinfections (PCP prophylaxis with TMP-SMX, fungal prophylaxis as indicated)
27
Monitor renal function (ganciclovir, foscarnet) and bone marrow (ganciclovir)
28
Multidisciplinary care: transplant infectious disease, hematology, oncology, ophthalmology, ICU as needed
29
Long-term follow-up for relapse and chronic complications

Which Department to Visit?

You can visit our Enfeksiyon Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Enfeksiyon Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Flu (Influenza)

Enfeksiyon Hastalıkları

Influenza is a seasonal contagious respiratory disease caused by influenza viruses; it presents with high fever, muscle pain, and severe fatigue.

COVID-19

Enfeksiyon Hastalıkları

COVID-19 is a contagious disease caused by the SARS-CoV-2 coronavirus with a wide clinical spectrum ranging from asymptomatic to severe pneumonia.

Upper Respiratory Tract Infection

Enfeksiyon Hastalıkları

Upper respiratory tract infections are diseases that include common cold, pharyngitis, sinusitis, and laryngitis, often of viral origin and self-limited.

Urinary Tract Infection

Enfeksiyon Hastalıkları

Urinary tract infections are common bacterial infections most often caused by Escherichia coli, presenting with burning and frequent urination.

Hepatitis A (HAV)

Enfeksiyon Hastalıkları

Hepatitis A is an acute, self-limited liver infection transmitted via the fecal-oral route causing acute hepatitis without chronicity; supportive care suffices in most cases, while vaccination prevents outbreaks and post-exposure prophylaxis within 2 weeks is effective.

Hepatitis B

Enfeksiyon Hastalıkları

Hepatitis B is a contagious infection caused by HBV virus transmitted via blood, sexual intercourse, and mother-to-child, that can become chronic and progress to cirrhosis and liver cancer.

Hepatitis C

Enfeksiyon Hastalıkları

Hepatitis C is a liver disease caused by HCV virus transmitted mainly by blood; the rate of chronicity is high, but cure is possible with new antiviral drugs.

HIV/AIDS Information

Enfeksiyon Hastalıkları

HIV is a virus that targets the immune system; if untreated, it progresses to AIDS. With modern antiretroviral therapy, HIV-positive individuals can lead healthy, long lives.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.